AALL1131; A Phase 3 Randomized Trial for HR B-ALL with Dasatinib Arm in Ph-like TKI Sensitive Mutations

AddtoAny

The study compares 2 different experimental chemotherapy combinations with the usual chemotherapy combination given during post-Induction therapy. The 3 treatment plans we will be using include: a) therapy containing the usual/standard drugs - Control Arm or, b) therapy containing cyclophosphamide and etoposide- Experimental Arm 1 or, c) therapy containing clofarabine, cyclophosphamide and etoposide – Experimental Arm 2.

Eligibility & Criteria

IRB #:

11-008530

Official Title:

AALL1131; A Phase III Randomized Trial for Newly Diagnosed High Risk B- Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (IND#73789, NSC#732517) in Patients with Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations

Study Phase:

Phase III

Eligible Age Range:

0 - 99 Years

Gender:

All

Study Categories:

Adults, Children

Leader

AALL1131; A Phase 3 Randomized Trial for HR B-ALL with Dasatinib Arm in Ph-like TKI Sensitive Mutations

WATCH THIS PAGE

This study is no longer recruiting.

Eligibility & Criteria

Susan R. Rheingold, MD

AALL1131; A Phase 3 Randomized Trial for HR B-ALL with Dasatinib Arm in Ph-like TKI Sensitive Mutations

WATCH THIS PAGE

This study is no longer recruiting.

Eligibility & Criteria

Susan R. Rheingold, MD

We Need Families Like You